Promising Results in EGFR-Mutated Lung Cancer with Iza-bren and Osimertinib Combination Therapy

A recent clinical study has revealed highly encouraging outcomes for patients with first-line EGFR-mutated non-small cell lung cancer (NSCLC) treated with a novel combination of iza-bren and osimertinib. Iza-bren, a groundbreaking bispecific antibody-drug conjugate (ADC) that targets EGFR and HER3 while delivering a topoisomerase I inhibitor payload, was paired with daily osimertinib, a third-generation EGFR tyrosine kinase inhibitor.

Presented at the 2025 World Conference on Lung Cancer, the study involved 154 patients across multiple dose levels. In particular, the group receiving 2.5 mg/kg of iza-bren achieved a 100% objective response rate (ORR), with a confirmed ORR of 95%, indicating that nearly all patients experienced tumor shrinkage. The median follow-up period was 12.8 months, with a 92.1% progression-free survival (PFS) rate at 12 months. Notably, the median duration of response and PFS had not yet been reached at the time of analysis.

The safety profile was manageable, with most treatment-related adverse events being hematologic, such as anemia (91.9%), neutropenia (91.1%), leukopenia (91.1%), and thrombocytopenia (75.6%). Non-hematologic side effects included nausea, stomatitis, decreased appetite, vomiting, diarrhea, and rash. Grade 3 or higher adverse events were controllable through supportive care and dose adjustments, with a discontinuation rate of 13%.

Dr. Fei Zhou, the lead investigator, expressed optimism about the findings, highlighting the potential for this combination to become a transformative first-line therapy for EGFR-mutant NSCLC. The promising activity and manageable safety profile suggest that future studies could solidify its place in lung cancer treatment options.

This groundbreaking research underscores ongoing advancements in targeted therapies for lung cancer, aiming to improve outcomes for patients with EGFR mutations.

For more details, visit the original report at Medical Xpress.